lunedì, 20 marzo 2023
7 Dicembre 2018

FDA Grants Atezolizumab Regimen Priority Review for Frontline SCLC

December 5, 2018 – The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The sBLA is based on the phase III IMpower133 study, in which adding atezolizumab to standard upfront carboplatin and etoposide significantly prolonged survival in patients with … (leggi tutto)